Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease

Phase 2

Completed

• Conditions: Hematological Malignancies
• Interventions: Procedure: Mesenchymal stem cell infusion

• Registration Number: NCT00504803
• Lead Sponsor: University of Liege

Brief Summary

Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study

Detailed Description

Not available

Study Timeline

• Study Start: 2006-12
• Study First Submitted: 2007-07-19
• Study First Submitted QC: 2007-07-19
• Study First Posted: 2007-07-20
• Primary Completion: 2010-12
• Study Completion: 2010-12
• Status Verified: 2011-09
• Last Update Submitted: 2011-09-01
• Last Update Posted: 2011-09-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	Mesenchymal stem cell infusion	MSC co-infusion with either HLA-mismatched PBSC or cord blood

Primary Outcome Measures

Name	Time	Method
Day-100 incidence of non-relapse mortality	100 days

Secondary Outcome Measures

Name	Time	Method
1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution	365 days

Trial Locations

Locations (1)

CHU Sart Tilman; 🇧🇪 Liege, Belgium